Get the Daily Brief
Latest Biotech News
Oral GLP‑1 race tightens: Lilly’s orforglipron review and label updates
Eli Lilly said the FDA is expected to decide on its oral obesity pill orforglipron in the second quarter of 2026 after granting Lilly a national priority review voucher intended to accelerate...
Illumina launches Billion Cell Atlas — pharma partners to power AI drug discovery
Illumina released the first installment of its Billion Cell Atlas, a genome‑wide genetic perturbation dataset designed to train AI models for drug discovery. Illumina named AstraZeneca, Merck and...
Liquid biopsy financing surges: Cyclomics raises €2.6M, Precede nets $84M
Dutch startup Cyclomics raised €2.6 million to move its Epinn methylation‑based cancer test and CyclomicsSeq assays toward CE‑IVD and eventual FDA clearance, aiming to commercialize its...
CRISPR clinic timeline: Scribe readies first in‑human study; Cas3 shows therapeutic promise
Scribe Therapeutics confirmed readiness to test its first CRISPR‑based therapeutic in humans this summer, moving the company’s novel CRISPR enzyme platform from preclinical development toward...
FDA removes suicide warning from GLP-1 labels – regulators update risk assessment
The FDA concluded a post-market evaluation and is moving to remove suicidal ideation and behavior warnings from labels for approved GLP‑1 obesity drugs. The agency’s review found no increased risk...
Illumina launches Billion Cell Atlas... AI drug discovery gets a training set
Illumina unveiled the Billion Cell Atlas, a genome‑wide genetic perturbation dataset intended to train foundation models for drug discovery and validate genetic targets at scale. Founding pharma...
Cellares signs lease in Leiden – European smart factory set for 2026
Cellares announced a long‑term lease for a new integrated development and manufacturing organization (IDMO) Smart Factory at Leiden Bio Science Park, establishing its European headquarters and...
Natera doubles down on Signatera: MRD upgrades and commercial cadence set for 2026
Natera executives said Signatera—its blood‑based minimal residual disease (MRD) assay—delivered record growth in Q4 2025 and will be enhanced with phased and structural variant tracking in a new...
PanMAN compresses pangenomes – a storage fix for large-scale genomics
Researchers from UC San Diego introduced PanMAN (Pangenome Mutation‑Annotated Network), a new file format and data structure that dramatically compresses large pangenome datasets while preserving...
Digital CRISPR diagnostics: Rapid C. auris detection and resistance profiling
A Wyss Institute team reported dSHERLOCK, a digital CRISPR‑based diagnostic that quantifies Candida auris and detects resistance mutations from swab samples with high sensitivity and speed. The...
J&J posts positive Phase 3 for Tecvayli – survival gains in earlier myeloma
Johnson & Johnson reported positive Phase 3 results for Tecvayli in an earlier‑line multiple myeloma setting, with survival outcomes supporting plans to expand use beyond later‑line indications....
Myriad maps MRD expansion at JPM – five cancer assays, early access plans
Myriad Genetics detailed a menu refresh at JP Morgan, committing to launch tissue‑informed minimal residual disease (MRD) tests across breast, renal, colorectal, endometrial, and ovarian cancers...
Thermo Fisher and NVIDIA partner to embed AI across lab instruments and workflows
Thermo Fisher announced a strategic collaboration with NVIDIA to integrate NVIDIA’s AI infrastructure and models into scientific instruments and lab automation platforms. The companies said the...
Gut microbiota steer tumor immunity – microbiome links to immunoresistance emerge
New studies connected gut microbiota to systemic T cell plasticity and tumor control, demonstrating that certain intestinal CD4+ T cells primed in the gut can traffic to tumors and adopt...
Illumina’s Billion Cell Atlas: AI drug discovery gets a cell‑scale training set
Illumina unveiled the Billion Cell Atlas, a genome‑wide genetic perturbation dataset intended to accelerate AI‑driven drug discovery. The company has generated data from hundreds of millions of...
Novo Nordisk Foundation to bankroll European biotech incubator: €5.5bn through 2035
The Novo Nordisk Foundation committed 5.5 billion Danish kroner (about $857 million) to the BioInnovation Institute to expand its life science and deep‑tech commercialization work from 2026...
FDA clears GLP‑1 labels of suicide link: warnings removed after review
The U.S. Food and Drug Administration told manufacturers that post‑market data do not support an increased risk of suicidal ideation or behavior tied to GLP‑1 receptor agonists approved for...
AbbVie signs MFN deal with White House: pledges manufacturing and price concessions
AbbVie reached a most‑favored‑nation pricing agreement with the White House and pledged substantial investments in U.S. manufacturing as part of the deal. The company said it will focus on...
NVIDIA and Lilly launch $1B AI co‑innovation lab: compute meets drug discovery
NVIDIA and Eli Lilly announced a five‑year, $1 billion co‑innovation AI lab to accelerate computing and AI applications in drug discovery and development. The agreement brings NVIDIA’s accelerated...
dSHERLOCK: CRISPR‑based digital assay quantifies Candida auris and resistance
Researchers at the Wyss Institute developed dSHERLOCK, a digital CRISPR‑based diagnostic that quantifies Candida auris load and resistance mutations from swabs in real time. The platform...